Targeting OLIG2 in GBM and Medulloblastoma Using CT-179, an Orally Delivered Small Molecule Entering Clinical Development

Time: 2:30 pm
day: Conference Day Two


  • Scientific rationale for targeting OLIG2 in GBM, medulloblastoma, and other
  • Preclinical data supporting the use of CT-179 alone and in combination with
    standard of care therapies
  • Overview of the early-stage clinical development plan for CT-179 in adults with recurrent and newly diagnosed GBM